Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Wuhan YZY Biopharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	76	100.07	126.28	196.68	153.52	83.09
Trading Asset Securities	-	-	-	-	15	2.5
Cash & Short-Term Investments	76	100.07	126.28	196.68	168.52	85.59
Cash Growth	-54.27%	-20.76%	-35.80%	16.71%	96.90%	-
Accounts Receivable	39.61	11.6	51.11	-	-	-
Other Receivables	2.61	3	6.83	16.03	0.66	-
Receivables	42.22	14.6	57.94	16.03	0.66	-
Inventory	2.38	3.29	4.26	5.77	10.62	8.91
Other Current Assets	10	13.95	32.86	31.62	59.16	31.14
Total Current Assets	130.61	131.9	221.34	250.1	238.96	125.64
Property, Plant & Equipment	42.78	42.04	45.41	50.38	54.55	59.96
Other Long-Term Assets	3.65	1.07	1.09	1.14	9.34	14.55
Total Assets	177.04	175.01	267.84	301.62	302.84	200.16

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.7	4.53	6.66	3.15	3.29	10.23
Accrued Expenses	28.87	36.54	38.65	34.99	18.96	10.65
Short-Term Debt	-	-	-	-	76.5	28
Current Portion of Long-Term Debt	138.62	100.01	75.82	89.5	-	-
Current Portion of Leases	0.03	0.25	0.36	0.46	0.17	0.4
Current Income Taxes Payable	0.25	0.4	0.47	0.5	0.45	0.36
Current Unearned Revenue	20.04	15.72	21.08	0.64	3.85	1.45
Other Current Liabilities	47.1	43.1	43.1	44.58	43.74	5.82
Total Current Liabilities	235.6	200.54	186.14	173.82	146.96	56.91
Long-Term Debt	-	27.5	51.08	-	-	-
Long-Term Leases	-	-	0.09	0.15	-	0.08
Total Liabilities	235.6	228.04	237.31	173.97	146.96	56.99

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	193.85	193.85	193.85	193.85	182	-
Additional Paid-In Capital	-	345.01	345.01	345.01	193.38	613.6
Retained Earnings	-	-595.12	-510.39	-412.79	-221.09	-572.44
Comprehensive Income & Other	-252.41	3.23	2.06	1.58	1.58	102
Shareholders' Equity	-58.56	-53.03	30.54	127.65	155.88	143.16
Total Liabilities & Equity	177.04	175.01	267.84	301.62	302.84	200.16

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	138.65	127.76	127.35	90.11	76.67	28.48
Net Cash (Debt)	-62.65	-27.69	-1.08	106.57	91.85	57.11
Net Cash Growth	-	-	-	16.02%	60.85%	-
Net Cash Per Share	-0.32	-0.14	-0.01	0.58	0.53	0.38
Filing Date Shares Outstanding	193.85	193.85	193.85	193.85	182	152.11
Total Common Shares Outstanding	193.85	193.85	193.85	193.85	182	152.11
Working Capital	-104.99	-68.64	35.2	76.28	92	68.73
Book Value Per Share	-0.30	-0.27	0.16	0.66	0.86	0.94
Tangible Book Value	-58.56	-53.03	30.54	127.65	155.88	143.16
Tangible Book Value Per Share	-0.30	-0.27	0.16	0.66	0.86	0.94
Buildings	-	15.4	15.4	15.04	15.04	15.04
Machinery	-	68.15	68.16	68.33	66.81	65.46
Construction In Progress	-	17.56	16.85	16.85	16.85	16.85
Leasehold Improvements	-	1.76	1.76	1.76	1.76	1.76

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 18, 2026

Data Sources Report a data error